E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Mycoplasma pneumoniae pneumonia |
|
E.1.1.1 | Medical condition in easily understood language |
Pneumonia caused by the bacteria Mycoplasma pneumoniae. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim is to determine if corticosteroid treatment, as an adjunct to antibiotics, are beneficial for the treatment of adults hospitalised with M. pneumoniae pneumonia. |
|
E.2.2 | Secondary objectives of the trial |
Identifying inflammatory fingerprints for prediction of severe M. pneumoniae infection. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Age >=18 years, active M. pneumoniae pneumonia defined as chest x-ray or CT-scan showing an infiltrate and positive M. pneumoniae PCR on sample taken from upper or lower airways, admitted to a study hospital, hypoxemia defined as having a peripheral oxygen saturation below 93% (measured by pulse oximetry) and a breathing rate of >20 breaths per minute without supplemental oxygen treatment, a negative pregnancy test taken before inclusion and usage of an acceptable effective method of contraception until treatment discontinuation if the participant is a woman of childbearing potential, written informed consent after meeting with a study physician and ability and willingness to complete follow up. |
|
E.4 | Principal exclusion criteria |
Significant growth of alternative lower airway pathogen such as Streptococcus pneumoniae or Haemophilus influenzae in sputum, known current gastric ulcer, pregnancy, breast feeding, diabetes mellitus, chronic obstructive airway disease, asthma, hypersensitivity to any ingredient in the bethamethasone, inability to give informed consent or significantly compromised immunity. Compromised immunity includes but is not limited to treatment with major immunosuppressive agents including high dose corticosteroids, anti-TNF agents, calcineurin inhibitors, mTOR inhibitors, lymphocyte depleting biological agents, chemotherapeutic anti neoplastic agents. Also patients with advanced HIV/AIDS, severe immunodeficiency such as hypoglobulinemia, decompensated liver cirrhosis and bone marrow transplant the last year will be excluded. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time to resolution of hypoxemia defined as no longer requiring additional oxygen, having a peripheral oxygen saturation above 92% measured with pulse oximetry after 20 minutes rest and a breathing rate of <20 breaths per minute. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Patients will be evaluated daily whilst admitted and a follow up visit will be done on day 28 and by phone on days 42 and 56. |
|
E.5.2 | Secondary end point(s) |
Improvement in subjective well-being, shortness of breath, and cough as determined by CAP score questionnaire, time to resolution of fever and discharge from hospital, impact on eradication of M. pneumoniae and identifyication of inflammatory fingerprints for prediction of severe M. pneumoniae infection. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Patients will be evaluated daily whilst admitted and a follow up visit will be done on day 28 and by phone on days 42 and 56. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |